Antiplatelets for prevention of pre-eclampsia: an individual patient data review

高血压是一种常见的妊娠并发症，每年影响约20，000名澳大利亚妇女。虽然大多数妇女和她们的婴儿都很好，但先兆子痫（定义为高血压和尿液中的蛋白质）是一个更严重的问题。重度先兆子痫与10-15%的孕产妇死亡有关。胎儿和新生儿死亡率也在上升。母婴发病率很高，主要原因是与怀孕有关的并发症、产科干预增加、胎儿生长受限和早产。到目前为止，我们还没有安全有效的方法来预防这种危及生命的疾病。血小板聚集（参与血液凝固）是已知的疾病的一部分，并可能导致母亲和胎盘的循环障碍。抗血小板药物，特别是低剂量阿司匹林，可能会预防或延迟先兆子痫的发展。一些试验和科克伦对所有试验（涉及30，000多名妇女）的系统评价表明，先兆子痫，早产和围产期死亡可以减少。然而，目前还不清楚哪些妇女会受益，在怀孕时应该开始治疗，以及什么剂量的阿司匹林既有效又安全。这一拟议的个体患者数据审查，其中从原始研究者那里收集了所有进入试验的女性的数据，包括潜在危害的缺失信息。这项建议是一项很好的资源投资，以获得妇女和卫生专业人员所需的信息，以决定是否使用阿司匹林。来自所有主要试验的国际研究者已经形成了一个合作来监督该项目：围产期抗血小板国际研究审查（巴黎）合作此外，通过国际合作开展工作将确保最高质量的数据可用性，以及在实践中对结果的认可和实施。

High blood pressure is a common complication of pregnancy affecting ~20,000 Australian women each year. Although most women and their babies do well, pre-eclampsia, defined as high blood pressure together with protein in the urine is a more serious problem. Severe pre-eclampsia is associated with 10-15% of maternal deaths. Fetal and newborn baby deaths are also increased. Mother and baby morbidity is high principally due to the associated complications in pregnancy, increased obstetric interventions, fetal growth restriction and preterm birth. As yet we have no safe and effective way of preventing this life threatening condition. Aggregation of platelets (involved in blood clotting) is known to be part of the disease and could lead to the disturbances in the circulation of the mother and the placenta. Antiplatelet agents, low dose aspirin in particular, might prevent or delay the development of pre-eclampsia. Some trials and a Cochrane systematic review of all trials (involving over 30,000 women) suggest that pre-eclampsia, preterm birth and perinatal death could be reduced. However, it is still not clear which women will benefit, when in pregnancy the treatment should start and what dose of aspirin is both effective and safe. This proposed individual patient data review in which data on all women who have been entered in trials is gathered from the original investigators, including missing information on potential harms. This proposal represents a good investment of resources to obtain the information needed by women and health professional to make decisions about the use of aspirin. International investigators from all the primary trials have already formed a collaboration to oversee the project: the Perinatal Antiplatelet Review of International Studies (PARIS) Collaboration Furthermore, working through an international collaboration will ensure the highest quality in data availability, as well endorsement and implementation of the results in practice.